Author pages are created from data sourced from our academic publisher partnerships and public sources.
Microfluidics and circulating tumor cells.
- Yi Dong, Alison M. Skelley, +7 authors D. Smirnov
- Medicine, Biology
- The Journal of molecular diagnostics : JMD
- 1 March 2013
Circulating tumor cells (CTCs) are shed from cancerous tumors, enter the circulatory system, and migrate to distant organs to form metastases that ultimately lead to the death of most patients with… Expand
Best practices for companion diagnostic and therapeutic development: translating between the stakeholders.
By 2012 the pharmaceutical industry has generally recognized the value proposition offered through 'personalized medicine': shorter regulatory reviews and higher prices as a tradeoff for a more… Expand
Quest for the Ideal Cancer Biomarker: An Update on Progress in Capture and Characterization of Circulating Tumor Cells
Building Value Through Biomarkers
An increased focus on biopharmaceutical product differentiation has altered the business environment, placing the industry under immense pressure to reengineer a flawed business model that relied… Expand
Detecting and classifying circulating tumor cell subclasses from On-Q-ity microfluidic chips using a customized imaging platform.
- David Tims, A. Milutinovic, +5 authors W. Carney
- Journal of clinical oncology : official journal…
- 20 October 2012
72 Background: Circulating tumor cells (CTCs) have clinical value in cancer diagnosis, prognosis, and treatment prediction. The On-Q-ity Microfluidic Chip (OnQchip) with a gradient design has the… Expand
Abstract 3507: Multiparameter CTC characterization using dual capture microfluidic chips.
- Chunsheng Jiang, Oleg Gusyatin, David Tims, Aladin Milutinovic, Kam M. Sprott, Michael Stocum
- 15 April 2013
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Circulating tumor cells (CTCs) have become increasingly acceptable as a prognostic marker in stratifying metastatic cancer… Expand
Abstract 3395: Clinical Survey of 19 actionable proteins in multiple indications using multiplex mass spectrometry
Many available oncology therapies are targeted to specific proteins, the most notable examples being therapies targeted to EGFR and Her2. For targeted therapies to have maximal efficacy, it is… Expand
P3.02Clinical Survey of actionable proteins in multiple indications using multiplex mass spectrometry
ABSTRACT Many available oncology therapies are targeted to specific proteins, the most notable examples being therapies targeted to EGFR and Her2. For targeted therapies to have maximal efficacy, it… Expand